Cardiovascular Risk in Patients with Dyslipidemia and Their Degree of Control as Perceived by Primary Care Physicians in a Survey—TERESA-Opinion Study

Vicente Pallarés-Carratalá, Vivencio Barrios, David Fierro-González, Jose Polo-García and Sergio Cinza-Sanjurjo ()
Additional contact information
Vicente Pallarés-Carratalá: Health Surveillance Unit, Unión de Mutuas, 12004 Castellón de la Plana, Spain
Vivencio Barrios: Cardiology Department, H Ramón y Cajal, 28034 Madrid, Spain
David Fierro-González: Armunia Health Centre, 24009 León, Spain
Jose Polo-García: Casar de Cáceres Health Centre, 10190 Cáceres, Spain
Sergio Cinza-Sanjurjo: Milladoiro Health Centre, 15895 Santiago de Compostela, Spain

IJERPH, 2023, vol. 20, issue 3, 1-11

Abstract: Objective: The aim of this study was to evaluate, through a survey, the opinion of primary care (PC) physicians on the magnitude of dyslipidemia and its degree of control in their clinical practice. Materials and methods: An ecological study was carried out, in which the physicians were invited to participate by means of an online letter. Data were collected at a single timepoint and were based only on the experience, knowledge, and routine clinical practice of the participating physician. Results: A total of 300 physicians answered the questionnaire and estimated the prevalence of dyslipidemia between 2% and 80%. They estimated that 23.5% of their patients were high-risk, 18.2% were very high-risk, and 14.4% had recurrent events in the last 2 years. The PC physicians considered that 61.5% of their patients achieved the targets set. The participants fixed the presence of side-effects to statins at 14%. The statin that was considered safest with regard to side-effects was rosuvastatin (69%). Conclusions: PC physicians in Spain perceive that the CVR of their patients is high. This, together with the overestimation of the degree of control of LDL-C, could justify the inertia in the treatment of lipids. Moreover, they perceive that one-sixth of the patients treated with statins have side-effects.

Keywords: cardiovascular risk; dyslipidemia; statins; side-effects (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/20/3/2388/pdf (application/pdf)
https://www.mdpi.com/1660-4601/20/3/2388/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:20:y:2023:i:3:p:2388-:d:1050359

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().